Skip to content
Search
Facebook
 
ADCSADCS
ADCS
Alzheimer's Disease Cooperative Study
  • About Us
    • About ADCS
    • Meet the Directors
    • ADCS Cores
    • ADCS Clinical Trials Network
    • Steering Committee Voting Members
  • Public & Participant Resources
    • About Alzheimer’s Disease
    • AD Resources
    • Clinical Sites
    • Types of Studies
    • Clinical Trials
    • Study Newsletters
    • Research News
    • Alzheimer’s Study Quilt Project
  • Investigator Resources
    • Publications
    • Study Resources
    • Data Sharing
    • Biospecimen Bank
    • ADCS Instruments
    • Proposal Submission
  • CTMS
    • Clinical Conductor Enterprise
    • Clinical Conductor Site Portals
  • Donate
  • Steering Committee Members
  • Staff Resources
  • About Us
    • About ADCS
    • Meet the Directors
    • ADCS Cores
    • ADCS Clinical Trials Network
    • Steering Committee Voting Members
  • Public & Participant Resources
    • About Alzheimer’s Disease
    • AD Resources
    • Clinical Sites
    • Types of Studies
    • Clinical Trials
    • Study Newsletters
    • Research News
    • Alzheimer’s Study Quilt Project
  • Investigator Resources
    • Publications
    • Study Resources
    • Data Sharing
    • Biospecimen Bank
    • ADCS Instruments
    • Proposal Submission
  • CTMS
    • Clinical Conductor Enterprise
    • Clinical Conductor Site Portals
  • Donate
  • Steering Committee Members
  • Staff Resources

Additional data from the Phase III Gammaglobulin Alzheimer’s Partnership (GAP) study, including select analyses of subgroups, biomarker and imaging data, was presented at the Alzheimer’s Association International Conference (AAIC) in Boston, Massachusetts

You are here:
  1. Home
  2. Research News
  3. Additional data from the Phase…

On cognitive measures, an analysis of ApoE4 carrier patients who were treated with the 400mg/kg biweekly dose (n=87) of immunoglobulin (IG), found a statistically significant difference (p=0.012) in change from baseline in the 3MS score at 18 months versus placebo.

Post navigation

PreviousPrevious post:Paul Aisen, MD, Director of the ADCS, expands on the significance of the ADCS DAPC independent analysis of the semagacestat trial which was published last week in the New England Journal of Medicine.NextNext post:When a neuron gets blocked, the delicate harmony that allows the brain to operate seamlessly deteriorates. One result: diseases like Alzheimer’s. Understanding such blockages and how “traffic” should flow normally in healthy brain cells could offer hope to people with neurodegenerative diseases.
ADCS Research News
  • Home Based Assessments Trial Primary Paper in the Journal of Alzheimer’s & Dementia
  • “Young Latino’s Working in Alzheimer’s” Airs Tonight on UCSD TV and is Streaming on the Brain Channel
  • 40 Sites Across The Country To Test New Alzheimer’s Drug
  • Newly discovered Alzheimer’s genes lead to hope for future treatments
  • ADCS Director Howard Feldman, MD talks about the T2 Protect trial and a bright future for Alzheimer’s research
About ADCS
The Alzheimer’s Disease Cooperative Study (ADCS) was formed in 1991 as a cooperative agreement between the National Institute on Aging (NIA) and the University of California San Diego.
Contact Us
  • E-mail:
    alzinfo@ucsd.edu
  • Phone:
    858-246-1333

Find us on:

FacebookRssMail
Location
Shipping Address:
9452 Medical Center Drive
4th Floor
La Jolla, CA 92037

Mailing Address:
9500 Gilman Dr
MC0949
La Jolla, CA 92093-0949
ADCS
Copyright 2017 Regents of the University of California.